IN DATE: 07/07/2003

ER TRADEN

PTO/SB/08b(05-03)

Sheet	Use as a O2	TION DISCLOSURE INT BY APPLICANT many sheets as necessary)  of 02  NON PATENT	Application Number 09 Filing Date 07 First Named Inventor Sp Art Unit 16 Examiner Name Je	primation unless it contains a valid OMB control number of the con	CC			
STATE  Sheet  (Caminer (itials*	Use as a O2	many sheets as necessary)  of 02	First Named Inventor Sp. Art Unit 16 Examiner Name Je Attorney Docket Number 28	pencer FARR, et al.  642 eanine Anne Goldberg 874-002	000			
Sheet xaminer (itials*	O2 Cite	many sheets as necessary) Of 02	Art Unit 16  Examiner Name Je  Attorney Docket Number 28	pencer FARR, et al. 642 eanine Anne Goldberg 674-002	000			
xaminer (itials*	02 Cite	of 02	Examiner Name Je Attorney Docket Number 28	eanine Anne Goldberg	200			
xaminer (itials*	02 Cite	of 02	Attorney Docket Number 28	eanine Anne Goldberg	<del>-</del>			
xaminer (itials*	Cite	V tu	Attorney Docket Number 28	374-002				
itials*		NON PATENT	ITERATURE DOCUMEN		25/			
itials*		NON PATENT	TIERATIRE INTERIORE	. I TA	<del>`%</del>			
itials*			LITERATURE DOCUMEN	NIS				
	No. <sup>1</sup>			(when appropriate), title of the item (book, volume-issue number(s), publisher, clty d.	T <sup>2</sup>			
$\mathcal{Y} = \mathcal{Y}$	06	KRAEMER, et al., Regulation of Pro 2,3,7,8-Tetrachlorodibenzo-p-dioxin Volume 330, No. 2, Article No. 0259	, Archives of Biochemistry ar , Academic Press, Inc.	nd Biophysics, 1996, 319-328,				
0	70	This Technology, Archives of Bioch	elopment of a Toxicological Gene Array and Quantitative Assessment of Biochemistry and Biophysics, 2000, 66-73, Volume 376, No. 1,					
o	08	SCHRAML, et al., Tissue Microarra	ays for Gene Amplification Surveys in Many Different Tumor An Official Journal of the American Association for Cancer					
o	9	FARR, et al., Concise Review: Ger 1999, 1-9, Volume 50, Society of To	ncise Review: Gene Expression Applied to Toxicology, Toxicological Sciences, ne 50, Society of Toxicology					
1	10	DNA Microarrays, Nature Medicine	ation and Identification of Secondary Drug Target Effects Using , 1998, 1293-1300, Volume 4, No. 11					
1	11	SCHENA, et al., Parallel Human Ge Genes, Proc. Natl. Acad. Sci. USA,	nome Analysis: Microarry-b 1996, 10614-10619, Volume	pased Expression Montoring of 1000 e 93				
J 1	12	Burczynski, et al., Toxicogenomics- Hepatoma Cells, Toxicological Scie	Based Discrimination of Toxi nces, 2000, 399-415, Volume	ic Mechanism in HepG2 Human	**********			

Examiner Signature	oldberg	Date Considered	u	18/03	
<u> </u>					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

7 2003 7,1				respond to a collection of information unless it contains a valid OMB control nu Complete if Known				
Substitute for form 1449A/PTO  DENDET NOTION DISCLOSURE  STATEMENT BY APPLICANT			Application Number 09/91		1.904			
			Filing Date	<del></del>	07/23/		~	
			First Name	ed Inventor	Spend	encer FARR, et al.		
3	STATEMENT BY APPLICANT			Art Unit		1642		100
		(Use as many sheets as necess	arv)	Examiner	Name	Jeanir	ne Anne Goldberg	
Sheet	01	<u> </u>	of 02	Attorney D	Oocket Number	2874-		
- Consess								
			U. S. PATEN		ENTS ime of Patentee or	<del></del> -	Pages, Columns, Lir	oc Wh
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YYYY		ant of Cited Docur		Relevant Passages of Figures Apple	r Relev
CX <b>9</b>	01	<sup>US-</sup> 5,654,401	08/05/1997	Cleme	nts et al.		<b>/</b>	
$\Omega_{-}$	ļ <u>.</u>	US-					оменация в денен разда-да-да-да-да-да то те предприти до дан ит ут од	P-1
on a graphy of the day a shell would be		US-			addresid (display) quant spino i menancia anti e e camana me			
e per a gloriage en en experience de la grapa de l'agranda de l'estado de l'es		US-			elikining-marahatini-biripenangena p-aus			
and committee principles and other high incomprising the first		US-		Marketon Marketon Strategy and	NAMES OF TAXABLE PARTY.			
garan nga ngangan kembalan kalang dan dan berakan ber		US-		***************************************	manden and single parties and constant of the William	***********		
	<b></b> -	US-			dender die der der vertreiten der vertreiten der			
	ļ	US-		***************************************	4) Metalendaria (Metalendaria			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ngangangangangan niliggangahat nabunan b	·	US-			and the state of t			
************************	ļ	US-			physical action in proper proper and an explicit only physical action to the establish			
	<b> </b> -	US-	The same of the sa	**************************************	ACCORDING THE PROPERTY OF THE			
- paragaranta atta ata i ta ata tita tita tita ti	<b></b> -	US-			MARIAN INNER SANCKARIN PROPERTY I SANCKAR SANCKAR SANCKAR SANCKAR SANCKAR			
consideration and the multiples problem systematic		US-			- The state of the			
	<b> </b>	US-	the first and the city time of the city of the \$40 km and the second representations.		and an account period of the head of the second particular second	***************************************		
nyanyanganganganas namas sa nafisirkini		US-			And the place ( to this place is a first of the first of			
anna taganatan kurupun bilat tagan tagan baran		US-			appen appropriate tricky pyratical business in 1980 to 1977	Martin Martin Service (1984)		
	-	US-	/ cell and the proceedings to the first the first between the first the second terms to	And the second s	efective representative and the second con- many speed on appearance of			
		US-		***************************************	.4(.p. 1(11))44/1 dissip 16:16:16 dissip 16:16:16:16:16:16:16:16:16:16:16:16:16:1			
					JMENTS			

FUREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> 'Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т <sup>6</sup>			
CXY	02	WO 00/12760	03/09/2000	Incyte Pharmaceuticals, Inc.					
U	03	WO 99/05320	02/04/1999	Rapigene, Inc.					
	04	EP 0 292 879 A2	11/30/1988	Orion Corporation Ltd.	***************************************				
V	05	WO 01/51667 A2	07/19/2001	Integriderm, L.L.C.					
*****************	1								

Date Considered Examiner Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents P.O. Box 1450, Alexandria VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.